195 results about "Choroid membrane" patented technology

The invention relates to the technical field of medical image processing and artificial intelligence, and discloses an artificial intelligence-based retinochoroid disease course structure change monitoring system, which comprises an image acquisition unit, a feature extraction unit, a lesion segmentation unit and the like. The image acquisition unit acquires retina optical coherence tomography sequence image data and fundus color image data; the feature extraction unit extracts a retina choroidal structure feature tensor through a three-dimensional convolutional neural network; the lesion segmentation unit outputs a lesion area probability distribution diagram by using a U-Net segmentation network; the time sequence alignment unit is used for registering the multi-time-point images to generate a displacement change matrix; the dynamic analysis unit extracts related indexes; an abnormal scoring unit constructs a disease course progress score; the decision grading unit outputs disease course stage classification labels; the multi-modal fusion unit fuses the multi-modal features; the report generation unit generates a structured disease course monitoring report. And favorable support is provided for diagnosis and treatment of ophthalmic diseases and illness state tracking.

The invention discloses a construction method and application of a histopathologic quantitative evaluation model of choroidal neovascularization, and the evaluation model constructed by the method can accurately identify a choroidal neovascularization structure around a laser spot, and can carry out rapid batch analysis on a large number of laid sheets. The reliability and the consistency of analysis results are improved, and differences caused by laser surgery, interference of manual operation factors and the labor cost of analysis are reduced.

An apparatus and method for aiding in the detection of dementia, concussion, other neurologic conditions, retinal, and optic nerve conditions. The apparatus enables the diffusion coefficient of the tissue to be ascertained and studied by directing the light from a laser or other coherent light source at the patient's retina, optic nerve or choroid and measuring the fluctuations in the intensity of the back-scattered light caused by the movement of light scatterers in the tissue. By comparing the measurements to a normal database, or to the subject's previous measurement, in combination with an eye examination and OCT image / measurement the changes caused by the disease and the effectiveness of therapy can be ascertained. The disclosed apparatus allows the incident and detection optics to be attached to ophthalmic devices typically used in ophthalmologic care. Also, where both the incident laser fiber optic and the detection fiber optic are directly connected to goggles, one or more or all of the above-described mirrors may not be necessary, as both fiber optics are preferably directly directed into the eye.

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.

The invention discloses a desktop remote image read-write device with contrast control and a control method thereof. The desktop remote image read-write device comprises a plane spectroscope, a concave reflector and a backlight plate. The light reflected by the desktop and an object placed on the desktop is emitted to the plane spectroscope from the lower part, and the light split by the plane spectroscope is reflected by the concave reflector, is split by the plane spectroscope again, is emitted to an exit pupil position and forms a far image at a position not less than 3 meters; brightness of different areas of the backlight plate is different so as to change contrast of different areas of a far image. According to the desktop far image read-write device, when a user reads characters and other contents in a book, the peripheral low-contrast visual effect is provided, the growth of an eye axis is further inhibited, meanwhile, a certain effect is achieved on thickening of a choroid, and myopia prevention and control are achieved.

By constructing an age-related macular degeneration animal model, experimental results in multiple aspects of clinical examination (FFA and ERG), pathological detection (RPE-choroidal patch IB4 fluorescent staining) and the like prove that the rucotinib can be used for effectively treating age-related macular degeneration, especially wet age-related macular degeneration.

The invention provides an OCTA image-based neovascularization segmentation method, training method, equipment and medium, and the method comprises the steps: obtaining an OCTA image to be recognized, and carrying out the choroidal neovascularization CNV segmentation of the OCTA image based on a segmentation model, and obtaining a CNV segmentation result. Namely, for the obtained OCTA image, the ResNeSt module in the segmentation model is utilized to carry out group convolution and attention separation feature learning, CNV features can be accurately identified from the OCTA image, and great convenience is brought to subsequent CNV quantization.

An image processing method performed by a processor includes: a step of acquiring a fundus image in which choroid blood vessels are visualized; a step of extracting choroid arteries in the fundus image acquired in the acquiring step by performing image processing on the fundus image; and a step of generating a fundus image in which the choroid arteries extracted in the extracting step are highlighted.

The present invention discloses a method for constructing a choroidal segmentation model for OCT images in combination with a priori masks and its application. The present invention includes data preprocessing, through cropping, adjusting the scale, and then cropping to unify the data size; then generating two-stage choroidal masks through annotation; to solve the problem of complex image background, a cascaded multi-stage segmentation network is designed. In the first stage, the part below the BM layer is segmented to remove the upper background interference, and the second stage is to finely segment the choroid; to solve the problem of uneven choroidal texture and blurred lower boundary, a multi-scale context aggregation module is designed; finally, to optimize the training process of the cascade network, an adaptive cross-stage feature fusion module is designed. The present invention fully utilizes the information of the optical coherence tomography image itself and can effectively capture the multi-scale information and contextual information of the image, thereby improving the choroidal segmentation effect of the optical coherence tomography image.

The application discloses an ophthalmic choroid burst hemorrhage principle teaching mold, a plurality of water injection holes are arranged on the upper portion of the mold on the choroid, a plurality of water injection pipes are arranged correspondingly to the water injection holes, the water outlets of the water injection pipes are communicated to the choroid and the retina through the water injection holes, the water inlets are gathered in the sclera external port for connecting with a syringe, so that the syringe is used to inject or suck out liquid, and choroid burst hemorrhage is simulated. The application also provides a use method of the mold. The ophthalmic choroid burst hemorrhage principle teaching mold and the use method thereof can simulate choroid burst hemorrhage caused by eye injury, intraocular surgery and the like, have strong simulation, can realize on-site operation, have strong intuitiveness, good visual communication effect, are easy to understand, are convenient to carry, are easy to use, and greatly improve the teaching effect.

The present application relates to the technical field of nanomedicine delivery system, and particularly relates to a slow-release liposome for treating choroidal neovascularization of fundus, a preparation method and application thereof. The slow-release liposome for treating choroidal neovascularization of fundus comprises a liposome shell loaded with brivanib and liquid fluorocarbon, and a cell penetrating peptide and an anti-CD105 antibody are connected to the liposome shell. The present application selects a double-target drug brivanib, and prepares a novel nanoparticle modified by a cell penetrating peptide and targeted to vascular endothelial cells. The nanoparticle can penetrate the blood-ocular barrier and the cell membrane into the cell interior under the mediation of the cell penetrating peptide, so that persistent, efficient and precise treatment of choroidal neovascularization is realized. The technical scheme can solve the technical problem that the prior art lacks a drug delivery system capable of simultaneously realizing long-acting release, breaking through multiple barriers in the eye and synergistically inhibiting multiple target pro-angiogenic factors, and has an ideal application and promotion prospect.

The invention discloses a double-drug-loading cationic mixed micelle as well as a preparation method and application thereof, and belongs to the field of pharmaceutics. The micelle is composed of a cationic polymer PEI-stearamide (PSA), an amphiphilic polymer DSPE-PEG2000, a hydrophobic drug resveratrol (RES) and a hydrophilic drug catalase (CAT). The preparation method comprises the following steps: 1) synthesizing PSA; the preparation method comprises 1, dissolving RES, PSA and DSPE-PEG2000 in an organic phase, injecting the obtained solution into a water phase, and carrying out rotary evaporation to obtain RES-loaded micelle (RES / PSA-PEG), and 3, adding a CAT solution to the micelle solution in a dropwise manner to obtain co-loaded micelle (RES / PSA-PEG / CAT). The micelle can effectively penetrate a corneal barrier and target a retinal pigment epithelial layer and a choroidal membrane.Through eye drop administration, RES anti-oxidation and anti-inflammatory effects and CAT hydrogen peroxide removal effects can be synergistically exerted, and an AMD curative effect can be substantially enhanced.

The present invention relates to antibodies that bind to VEGF and ANG2 for use in the treatment of ocular vascular diseases, such as neovascular AMD (nAMD) (also referred to as choroidal angiogenesis [CNV] secondary to age-related macular degeneration [AMD] or wet AMD), diabetic retinopathy, in particular diabetic macular edema (DME) or macular edema secondary to retinal vein occlusion (RVO).

The present invention relates to an apparatus (110) and a method (210) configured to determine a choroidal topography (218) on a region (114, 114') of the retina (116) of a human eye (117), and to the use of the apparatus (110) for determining the effect of at least one ophthalmic lens design on the choroidal topography (218). In this document, the device (110) includes: - at least two separate displays (122, 122'), each configured to provide retinal stimulation (112, 112'), thereby providing two independent retinal stimuli (112, 112'); - at least two optical transmission elements, including a first optical transmission element and a second optical transmission element, each configured to project at least one of the retinal stimulation (112, 112') or a phase map onto a region of the retina of a human eye, wherein the phase map includes a modified retinal stimulation; - a measuring device (142) for capturing a human eye by using reflected light received from a region (114, 114') on the retina (116) of the human eye (117). (117) Choroidal topography (218) on region (114, 114') of retina (116); - Optical filter (152) configured to separate reflected light received from region (114, 114') of retina (116) of human eye (117) from phase map of region (114, 114') of retina (116) of human eye (117), wherein the second optical transmission element is further configured to simultaneously project each of the at least two separate phase maps at different retinal eccentricities onto each of at least two separate regions (134, 134') of retina (116) of human eye (117), wherein these separate regions (134, 134') include peripheral region and foveal region of retina (116) of human eye (117).

An image processing method comprising acquiring a first fundus image obtained by photographing a fundus using first light having a first wavelength, and a second fundus image obtained by photographing the fundus using second light having a second wavelength that is shorter than the first wavelength; specifying, in the first fundus image, respective positions of retinal blood vessels appearing in the second fundus image; and generating a choroidal blood vessel image by processing the positions identified in the first fundus image.

This invention provides a method and device for refractive development assessment based on visual development prediction neural circuits, relating to the field of myopia management technology. The method includes: acquiring color retinal optical imaging signals and refractive ground state quantification values ​​of the subject; performing retinal stabilization preprocessing; extracting multi-level morphological features through a reentrant layered retinal choroid encoder; performing spatial feature aggregation gating on the extracted feature maps to obtain feature vectors; concatenating and integrating the feature vectors with the refractive ground state quantification values ​​to obtain fused feature vectors; constructing a fused feature vector sequence and inputting it into a refractive development dynamics internal model inferrer to generate a future multi-time-point refractive state prediction sequence; converting it into an interpretable refractive state numerical sequence; and providing risk warnings based on preset risk thresholds. This invention explicitly embeds physiological mechanisms prior into the model structure and parameter adaptive strategies, thereby maintaining the stability and interpretability of predictions even in a single medical visit scenario.

The invention belongs to the technical field of biological medicines, and relates to application of an FGF2 inhibitor in preparation of a medicine for treating retina and choroidal neovascular diseases. An oxygen-induced retinopathy (OIR) mouse model and a novel small molecule compound are used for researching related mechanisms in retinopathy neovascularization, and the treatment effect of the small molecule compound is evaluated. Results show that the Refi-10 disclosed by the invention can be used for treating vascular retinopathy by inhibiting FGF2 targets, and a replacement or supplement method of VEGF (vascular endothelial growth factor) inhibiting drugs is provided.

The application discloses a choroid neovascularization image segmentation method based on a hybrid convolutional network, first, collecting fundus OCT scan images and labeling, and forming a data set by using the labeled images; a deep space-time separation hybrid convolutional neural network fusing an attention mechanism is constructed, two-dimensional feature extraction is carried out by using two-dimensional convolution, then the two-dimensional feature extraction is extended to three-dimensional, and then three-dimensional attention deep space-time separation convolution is carried out, and the two-dimensional feature and the three-dimensional feature are aligned and fused; then the hybrid neural network model constructed is trained by using the data set; finally, the trained hybrid neural network model is used to segment choroid neovascularization from the fundus OCT scan images, and a segmentation result is obtained. Through the space-time attention mechanism, local features of the choroid neovascularization image are better extracted, and by using the deep space-time separation convolution, a dimension reduction operation is carried out on the input feature map, so that the calculation parameters can be effectively reduced, thereby reducing the network calculation amount, and the channel attention can be more effectively calculated.

A System / Method / Device for segmenting the choroid-scleral layer from an optical coherent tomography (OCT) volume scan. The present system uses a deep learning machine model based on a neural network that include multiple convolution layers, but no deconvolution layers. Rather, the present neural network is based on a novel architecture based on the discrete cosine transform.

Composition and methods are provided for the treatment of ocular hypertension or glaucoma, wherein intraocular pressure (IOP) is lowered by insertion of an implant suprachoroidal spacer into the suprachoroidal space

The present invention relates to an apparatus (110) and a method (210) configured determining a choroidal topography (218) over a region (114, 114') on a retina (116) of an eye (117) of a person as well as to a use of the apparatus (110) for determining an effect of at least one ophthalmic lens design on the choroidal topography (218). Herein, the apparatus (110) comprises: - at least two individual displays (122, 122') each configured for providing a retinal stimulus (112, 112'), thereby providing two independent retinal stimuli (112, 112'); - at least two optical transfer elements, comprising a first optical transfer element and a second optical transfer element, each configured for projecting at least one of the retinal stimulus (112, 112') or a phase map to a region on a retina of an eye of a person, wherein the phase map comprises a modified retinal stimulus; - a measuring device (142) for capturing a choroidal topography (218) over the region (114, 114') on the retina (116) of the eye (117) of the person by using reflected light received from the region (114, 114') on the retina (116) of the eye (117) of the person; - an optical filter (152) configured for separating the reflected light received from the region (114, 114') on the retina (116) of the eye (117) of the person from the phase map projected to the region (114, 114') on the retina of the eye of the person, wherein the second optical transfer element is further configured for simultaneously projecting each of the at least two individual phase maps at a different retinal eccentricity to each of at least two separate regions (134, 134') on the retina (116) of the eye (117) of the person, wherein the separate regions (134, 134') comprise a peripheral region and a foveal region on the retina (116) of the eye (117) of the person.

The invention provides a subretinal effusion region segmentation and volume calculation method and system, a product and a terminal, and the method comprises the steps: automatically segmenting a fundus prediction lesion region image based on a pre-constructed fundus lesion region prediction model, and carrying out the summation of pixel points, belonging to a subretinal effusion part, in the data of each fundus prediction lesion region image. According to the method, the volume data of the subretinal fluid is obtained, the film reading time of a fundus disease doctor is greatly shortened, the working efficiency is improved, in addition, the film reading accuracy, stability and homogeneity can be remarkably improved, and clinical doctors can be helped to accurately and objectively evaluate the central serous chorioretinopathy.

The present invention addresses the problem of providing an inhibitor for retinochoroidal disorders, in particular, an inhibitor for retinochoroidal scar formation and retinochoroidal atrophy in an epiretinal, intraretinal or subretinal tissue. This problem can be solved by preparing an inhibitor for retinochoroidal disorders which comprises, as an active ingredient, (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof or a salt of the same. The inhibitor for retinochoroidal disorders can inhibit collagen atrophy of retinal pigment epithelium cells, fibroblasts, glial cells and the like and thus inhibit retinochoroidal disorders.

To enable understanding of choroidal asymmetry. [Solution] In choroidal vascular images, the direction of blood vessel course is determined for each of several pairs of analysis points that are symmetrical with respect to the line connecting the macula and the optic nerve head. The asymmetry of each pair of analysis points is analyzed from the direction of blood vessel course of each analysis point, and the pair of analysis points with asymmetry is highlighted by enclosing them in a frame.

This image processing device executes processing that includes: acquiring a tomographic image in the depth direction including choroidal blood vessels and sclera; executing emphasis processing that emphasizes a physical quantity indicating a brightness change in the depth direction in the tomographic image with respect to a partial region of the tomographic image; deriving an image feature amount pertaining to the brightness change in the depth direction in the emphasized region; and determining, on the basis of the image feature amount, a site on the tomographic image in which the image feature amount exceeds a predetermined threshold as a boundary between the choroidal blood vessels and the sclera.

The application discloses a choroid layer and choroid blood vessel segmentation method, system and device, and relates to the technical field of image processing. The method comprises the following steps: acquiring a target OCT choroid image; preprocessing the target OCT choroid image to generate a target choroid dataset; inputting the target choroid dataset into a pre-trained ASPP-SE-U-Net network for prediction; the ASPP-SE-U-Net network comprises a choroid CNN model and a choroid blood vessel CNN model; the step of inputting the target choroid dataset into the pre-trained ASPP-SE-U-Net network for prediction comprises the following steps: generating a choroid segmentation prediction map according to the choroid CNN model, generating a choroid blood vessel segmentation prediction map according to the choroid blood vessel CNN model and the choroid segmentation prediction map, superimposing the choroid segmentation prediction map and the choroid blood vessel segmentation prediction map to generate a choroid layer and choroid blood vessel segmentation map. According to the application, the segmentation result is more accurate.

Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation are provided. In particular, a method of treating choroidal neovascularisation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a mineralocorticoid receptor antagonist is provided.

The present disclosure provides for one or more embodiments for treating retinal degenerative disorders in a subject by administering to the subject an effective amount of allogeneic mesenchymal stem cells to the subject's suprachoroidal area. Allogeneic mesenchymal stem cells, when used in the disclosed treatment regimen, may exhibit anti-inflammatory, immunomodulatory, anti-fibrotic, pro-vascular, and / or pro-regenerative processes. Thus, allogeneic mesenchymal stem cells may be understood to have the potential to target and treat multiple pathological targets implicated in retinal degenerative disorders, including retinal disorders characterized by drusen accumulation, some of which have inherited forms.

To provide an image processing method for analyzing choroidal blood vessels.SOLUTION: The method includes a step of acquiring an OCT image of a subject's eye by optical coherence tomography (OCT), a step of extracting a region other than a structure of the subject's eye in the OCT image, and a step of generating a first display screen in which position information on a scan position for acquiring the OCT image is superimposed on the region.SELECTED DRAWING: Figure 10

The invention belongs to the technical field of biological medicines, and particularly relates to application of emipril in preparation of a medicine for improving choroidal neovascularization related diseases. The invention aims to solve the problems of strong invasiveness and limited curative effect of the existing therapy. It is found that emipril can achieve differential regulation and control on a CD26 system in vivo, that is, the enzyme activity of CD26 in bone marrow is improved, the enzyme activity of CD26 in peripheral blood is reduced, the concentration gradient of stromal cell-derived factor-1 can be established between the bone marrow and the peripheral blood through differential regulation and control, and the concentration gradient of the stromal cell-derived factor-1 can be further improved. The bone marrow-derived cells are driven to homing to eye lesions and differentiate into repair cells, so that eye diseases are repaired or improved, meanwhile, the collection and migration of bone marrow-derived macrophages to CNV regions can be increased, and the anti-inflammatory effect is achieved. According to the application, an endogenous repair mechanism is activated through non-invasive administration, and a safer and more effective treatment method is provided for related eye diseases.